Clincosm LogoSign in Get a demo

metastatic

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Middletown, New Jersey
  • +5 more
Aug 17, 2023

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at

Withdrawn
  • CCR5
  • +3 more
  • 700mg leronlimab weekly dose
  • +3 more
  • (no location specified)
Feb 15, 2023

Breast, Metastatic, Triple Negative Trial in Gainesville, Jacksonville (Capecitabine, Sarilumab 150mg or 200 mg plus

Active, not recruiting
  • Breast
  • +4 more
  • Gainesville, Florida
  • +1 more
Feb 2, 2023

Predictive Factors and Biological Imaging of Response to

Completed
  • Metastatic
  • Breast Cancer
  • Bordeaux, France
  • +18 more
Jan 25, 2023

Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)

Active, not recruiting
  • Metastatic
  • +4 more
  • Radiotherapy
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 6, 2023

Pancreatic Adenocarcinoma, Metastatic Trial in Spain, United States (Nab-paclitaxel, Gemcitabine, VCN-01)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • Metastatic
  • New York, New York
  • +7 more
Jan 3, 2023

Uveal Melanoma, Metastatic Trial in Tampa (4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201)

Recruiting
  • Uveal Melanoma
  • Metastatic
  • 4.7 microCi 225Ac-MTI-201
  • +11 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 9, 2022

Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic Trial in Guangzhou (Surufatinib)

Recruiting
  • Adenocarcinoma of Small Intestine
  • +2 more
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Jul 22, 2022

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022

HER2-positive Breast Cancer, HER2 Low, SYD-985 Trial in Aurora (Vic-trastuzumab duocarmazine (SYD985) + paclitaxel)

Recruiting
  • HER2-positive Breast Cancer
  • +26 more
  • Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
  • Aurora, Colorado
    University of Colorado Cancer Center
Oct 22, 2021

Genomic Profiling Methods and Timing in Tumor Samples

Completed
  • Colorectal Cancer
  • +5 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    May 8, 2018

    Metastatic, Uveal Melanoma Trial in Worldwide (75mg selumetinib, , Dacarbazine)

    Completed
    Has Results
    • Metastatic
    • Uveal Melanoma
    • 75mg selumetinib
    • +2 more
    • Los Angeles, California
    • +30 more
    Jan 4, 2017

    Prostate Cancer, Metastatic, Hormone Refractory Trial in Worldwide (Zactima (vandetanib), Docetaxel, Prednisolone)

    Completed
    Has Results
    • Prostate Cancer
    • +2 more
    • Zactima (vandetanib)
    • +2 more
    • Rio de Janeiro, Brazil
    • +10 more
    Aug 25, 2016

    Metastatic, Colorectal, Adenocarcinoma Trial in Gent, Belfast, Manchester (ZD6474 (vandetanib) 100mg, Irinotecan,

    Completed
    • Metastatic
    • +2 more
    • ZD6474 (vandetanib) 100mg
    • +4 more
    • Gent, Belgium
    • +2 more
    Aug 24, 2016

    Non Small Cell Lung Cancer, Metastatic Trial in Athens, Heraklion, Thessaloniki (Bortezomib, Gemcitabine, Cisplatin)

    Completed
    • Non Small Cell Lung Cancer
    • Metastatic
    • Athens, Greece
    • +4 more
    Sep 25, 2015

    Unresectable, Locally Advanced, Metastatic Trial in Vienna (Cetuximab + Gemcitabine + Oxaliplatin)

    Completed
    • Unresectable
    • +2 more
    • Cetuximab + Gemcitabine + Oxaliplatin
    • Vienna, Austria
      KH Rudolfstiftung
    Oct 6, 2010

    Stomach Tumor, Metastatic, Second-Line Trial in Incheon (irinotecan, ILF)

    Unknown status
    • Stomach Neoplasm
    • +2 more
    • Incheon, Korea, Republic of
      Gachon University Gil Medical Center
    Jul 31, 2007